Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual

European Journal of Clinical Pharmacology

Volumn 65, Issue 1, 2009, Pages 97-100

  Gaedigk, Andrea ^a   Frank, Dorothee ^b   Fuhr, Uwe ^b  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6;

ADULT; ALLELE; CASE REPORT; CLINICAL FEATURE; CYP2D6 GENE; DRUG METABOLISM; GENE; GENE IDENTIFICATION; HUMAN; LETTER; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HAPLOTYPES; HUMANS; MALE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 57849102018     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0559-6     Document Type: Letter

References (9)

1. UM Zanger S Raimundo M Eichelbaum 2004 Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry Naunyn-Schmiedeberg's Arch Pharmacol 369 23 37
2. D Tomalik-Scharte A Jetter M Kinzig-Schippers 2005 Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers Drug Metab Dispos 33 1859 1866
3. C Wyen U Fuhr D Frank 2008 Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients Clin Pharmacol Ther 84 75 82
4. A Gaedigk SD Simon RE Pearce 2008 The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype Clin Pharmacol Ther 83 234 242
5. T Fukuda Y Nishida S Imaoka 2000 The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6 Arch Biochem Biophys 380 303 308
6. S Raimundo C Toscano K Klein 2004 A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects Clinical Pharmacol Ther (CPT) 76 128 138
7. H Shen MM He H Liu 2007 Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17 Drug Metab Dispos 35 1292 1300
8. A Soyama Y Saito T Kubo 2006 Sequence-based analysis of the CYP2D6*36-CYP2D6*10 tandem-type arrangement, a major CYP2D6*10 haplotype in the Japanese population Drug Metab Pharmacokinet 21 208 216
9. C Toscano K Klein J Blievernicht 2006 Impaired expression of CYP2D6 in intermediate metabolizers carrying the*41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events Pharmacogenet Genomics 16 755 766